ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 80 filers reported holding ENANTA PHARMACEUTICALS INC in Q1 2014. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $265,000 | -46.8% | 5,110 | -48.4% | 0.00% | -50.0% |
| Q2 2020 | $498,000 | +4.2% | 9,911 | +24.7% | 0.00% | +33.3% |
| Q3 2019 | $478,000 | +113.4% | 7,950 | +200.0% | 0.00% | +200.0% |
| Q2 2019 | $224,000 | +1.8% | 2,650 | -14.5% | 0.00% | 0.0% |
| Q4 2018 | $220,000 | -40.1% | 3,100 | -27.9% | 0.00% | -50.0% |
| Q3 2018 | $367,000 | +35.9% | 4,300 | -18.9% | 0.00% | 0.0% |
| Q4 2014 | $270,000 | -28.2% | 5,300 | -44.2% | 0.00% | -33.3% |
| Q3 2014 | $376,000 | -14.7% | 9,500 | -5.0% | 0.00% | 0.0% |
| Q1 2014 | $441,000 | – | 10,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 564,102 | $42,184,000 | 14.63% |
| Fairmount Funds Management LLC | 387,400 | $28,970,000 | 9.55% |
| Soleus Capital Management, L.P. | 318,275 | $23,801,000 | 2.38% |
| Darwin Global Management, Ltd. | 166,190 | $12,428,000 | 1.90% |
| Paradigm Biocapital Advisors LP | 75,507 | $5,646,000 | 1.61% |
| ARMISTICE CAPITAL, LLC | 1,056,000 | $78,968,000 | 1.29% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 150,000 | $11,217,000 | 1.29% |
| Portland Global Advisors LLC | 75,869 | $5,673,000 | 0.95% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,573,829 | $117,691,000 | 0.59% |
| Yorktown Management & Research Co Inc | 10,400 | $778,000 | 0.52% |